MedTrace Logo

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

NCT05241535 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2023-05-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

MT-7117

oral

DRUG

moxifloxacin

oral

DRUG

Placebo

oral

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma America Inc.

    lead INDUSTRY

Principal Investigators

  • Head of Medical Science · Mitsubishi Tanabe Pharma America Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-12
Primary Completion
2022-02-23
Completion
2022-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05241535 on ClinicalTrials.gov